Core Insights - Adia Nutrition Inc. has partnered with Dr. Asa Andrew, a prominent health talk show host, to promote its stem cell therapies and enhance public awareness of regenerative medicine [2][5][6] Company Overview - Adia Nutrition Inc. is a publicly traded company based in Winter Park, Florida, specializing in stem cell and regenerative products, including AdiaVita and AdiaLink [6] - The company operates Adia Med clinics that focus on orthopedic, pain management, and wound repair, offering advanced treatments such as stem cell therapies and platelet-rich plasma (PRP) [6][7] Partnership Details - Dr. Asa Andrew will serve as the official media partner for Adia Med, creating exclusive content across various platforms to educate the public about stem cell therapy and its benefits [4][5] - The partnership aims to increase awareness, education, and access to life-changing treatments in the field of regenerative medicine [5][6] Business Model - Revenue for Adia Nutrition Inc. is generated through service fees, product sales, equity stakes, and insurance billing for healthcare treatments [7] - The company is expanding its offerings to include insurance-billable wound care products through its lab division, Adia Labs LLC [6][7]

Core Viewpoint - Shineco, Inc. has announced the acquisition of a 51% equity interest in InfiniClone Limited, a biotechnology company specializing in regenerative medicine, marking a significant step into the stem cell technology sector [2][3][6]. Company Overview - Shineco, Inc. focuses on providing innovative diagnostic medical products and related medical devices, aiming to improve quality of life through safe and efficient health solutions [7]. - The company has developed 33 types of in vitro diagnostic reagents and related medical devices, alongside producing and selling healthy foods [7]. Acquisition Details - The acquisition involves a payment of $19,895,600 in cash and the issuance of 3,450,000 shares of common stock to the seller, Dr. Lim Kah Meng [3]. - InfiniClone holds 29 global patents, including five invention patents, which cover major markets such as the US, Europe, and Asia, providing a competitive edge in stem cell technology [4]. InfiniClone's Technology - InfiniClone's core technologies include cell reprogramming, stem cell culture using microcarrier technology, and the management of induced pluripotent stem cell (iPSC) libraries, which can enhance cell expansion throughput by three to ten times compared to existing methods [4]. - The technology is expected to reduce production costs per cell by over 60% and significantly shorten the time required for clinical applications, such as treating Parkinson's and Alzheimer's diseases [4]. Leadership and Expertise - Dr. Lim Kah Meng, the founder of InfiniClone, has over 20 years of experience in molecular research related to stem cell and regenerative medicine, and has founded several biotechnology companies [5]. - Shineco's CEO, Jennifer Zhan, emphasized the acquisition as a key milestone for entering the regenerative medicine field and highlighted the potential for transforming InfiniClone's technology from laboratory to clinical applications [6].

As filed with the Securities and Exchange Commission on September 28, 2023 Registration No. 333-______________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Elevai Labs, Inc. (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant's Name into English) (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code ...